NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

ANTERIS TECHNOLOGIES LTD (AVR)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 FROMTO
ANTERIS TECHNOLOGIES LTD22/05/2020
ADMEDUS LTD25/11/201322/05/2020
ALLIED HEALTHCARE GROUP LTD01/07/201125/11/2013
BIOMD LIMITED01/07/2011

Shareholder links

 

REGISTRY:

Computershare Perth
Level 17, 221 St Georges Terrace, Perth WA 6000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail

Company details

ISIN: AU0000088841
Address: Toowong Tower Level 3, 9 Sherwood Rd Toowong QLD 4066
Tel:  +61 (0)8 9266 0100Fax: +61 (0)8 9266 0199

Date first listed: 24/03/2004
Company Secretary: Steve Denaro
Sector: Health Care Equipment & Services Industry Group: XHJ
Activities: Innovative Healthcare Solutions - developing, investing and delivering leading edge medical technologies

News & Events

Expand this box to read and print

The suspension of trading in the securities of Anteris Technologies Ltd will be lifted immediately following the release by AVR of an announcement regarding a capital raising.

26/10/2023

The company releases a notice of proposed issue of securities.

26/10/2023

The company has raised $40 million with the issue of two million new ordinary shares at $20 per new share. The funds will be used for preparation for the FDA Pivotal trial of the Company's DurAVRâ„¢ THV for treating severe aortic stenosis, continued Valve-in-Valve trials and general working capital expenses. The Placement will settle in two tranches of $33.8m on 1 November 2023 and a second tranche of $6.2m anticipated for 15 November 2023.

26/10/2023

Anteris reports unprecedented positive hemodynamic results from the Interim Analysis of its US-EFS Trial for DurAVRTM THV.

25/10/2023

The securities of Anteris Technologies Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of AVR, pending the release of an announcement regarding capital raising.

25/10/2023

The suspension of trading in the securities of Anteris Technologies Ltd will be lifted immediately, following the release by AVR of an announcement regarding a proposed capital package.

06/01/2021

The company issues a notice of Proposed issue of Securities - AVR.

06/01/2021

$20M in a funding package principally for the Company's TAVR research and development including general working capital expenses. Facility provided by Mercer Street Global Opportunity Fund, LLC, a New York based investment fund.

06/01/2021

The company has entered into a short-term facility for the advance of $1,220,000 that provides the company with immediate funds equivalent to its forecasted research and development tax incentive offset for the majority of the 2020 calendar year.

04/01/2021

The company releases an Appendix 2A.

30/12/2020

1.1M raised in a placement to sophisticated investors at $3.37 per share "“ 10% discount to the last closing share price. Provides working capital as Anteris continues to demonstrate superior performance of the DurAVRâ„¢, 3D single-piece, aortic valve.

30/12/2020

The securities of Anteris Technologies Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of AVR, pending the release of an announcement regarding a proposed capital package.

29/12/2020

name changed from Admedus Ltd

22/05/2020

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    07/03/2022Steve Denaro2,222$18.020$40,040
    07/06/2021Steve Denaro5,000$8.009$40,047
    04/03/2016Wayne Paterson30,000$0.560$16,800

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    John SeabergChairman, Independent Director10/10/2014
    Wayne PatersonCEO, Managing Director10/10/2014
    David St. DenisCOO09/06/2017
    Matthew McDonnellCFO23/11/2018
    Wenyi GuNon Exec Director04/10/2018
    Steve DenaroNon Exec Director31/10/2018

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Yanheng WuNon Exec Director12/12/201815/12/2020
    Lishan ZhangNon Exec Director12/12/201830/05/2019
    Catherine CostelloExecutive Director, CFO01/11/201716/11/2018
    Simon BuckinghamNon Exec Director17/02/201704/10/2018
    Mathew RattyNon Exec Director27/05/201620/05/2018
    Mark ZiirsenCFO26/08/201601/11/2017
    Julian ChickCOO01/01/201209/06/2017
    Michael BennettExecutive Director16/07/200317/02/2017
    Stephen MannCFO10/10/201126/08/2016
    Lee RodneManaging Director, CEO16/06/201130/06/2016
    Chris CatlowChairman16/06/201109/02/2016
    Graeme RowleyNon Exec Director16/06/201109/02/2016
    Peter TurveyIndependent Director18/05/201208/02/2016
    Jet SoedirdjaNon Exec Director16/06/201118/05/2012
    Robert TownerNon Exec Director16/07/200303/04/2012
    Robert ScottNon Exec Chairman23/06/199916/06/2011

    Date of first appointment, title may have changed.